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Sepsis is a life-threatening condition caused by the inﬂammatory response to invading organisms.
Polymyxin B-immobilized ﬁber column direct hemoperfusion (PMX-DHP) is used to reduce blood
endotoxin levels and modulate circulating inﬂammatory cytokine levels in sepsis patients. Here we
report that severe sepsis caused by an infection of the gram-negative bacterium Pantoea agglomerans in a
patient with small cell lung carcinoma was treated successfully with antibiotics and PMX-DHP. The
patient, a 49-year-old Japanese male smoker whose condition was complicated with hyponatremia due
to SIADH (syndrome of inappropriate secretion of antidiuretic hormone), rapidly developed sepsis and
disseminated intravascular coagulation (DIC) after the administration of cisplatin and irinotecan. Despite
initial antibiotics therapy, severe host responses including hypotension, high body temperature and
tachycardia were noted. We initiated PMX-DHP, and the patient's Sequential Organ Failure Assessment
score was greatly reduced and his DIC improved immediately. To our knowledge, this is the ﬁrst reported
case of PMX-DHP therapy for severe sepsis caused by P. agglomerans infection. Although the efﬁcacy of
PMX-DHP in sepsis is not well deﬁned, PMX-DHP therapy should be considered in cases of sepsis from
gram-negative infections.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Small cell lung carcinoma (SCLC) is a common cancer type in
bronchogenic carcinomas. The features of SCLC include rapid
growth, early disseminated metastasis and highly responsivity to
chemotherapy. Although chemotherapy for SCLC can effectively
reduce the tumor size, some SCLC patients undergoing chemo-
therapy are exposed to severe infection, which is attributed to their
immunocompromised condition. Pantoea agglomerans
(P. agglomerans) is a gram-negative bacterium found in soil, water,
plant and the intestinal tracts of human and animals [1e3].
Little has been reported on the infectious conditions of
P. agglomerans [4], but P. agglomerans has described as a pathogenspirology, Endocrinology and
ty of Medicine, University of
ki-u.ac.jp (H. Tsubouchi).
Ltd. This is an open access article ufor arthritis [5], pneumonia [6], peritonitis [7], and sepsis [3,4,8] in
immunocompromised hosts, including patients undergoing
chemotherapy. Polymyxin B-immobilized ﬁber column direct
hemoperfusion (PMX-DHP) therapy has been used to remove li-
popolysaccharides (LPS) from gram-negative organisms in sepsis
patients. Although it has been documented that PMX-DHP
improved patients' Sequential Organ Failure Assessment (SOFA)
score and reduced 28-day mortality in a prospective randomized
controlled trial [9], the results obtained to date regarding the efﬁ-
cacy of PMX-DHP in sepsis are controversial [10].
Here, we report that severe sepsis caused by a P. agglomerans
infection in an SCLC patient undergoing cisplatin-based chemo-
therapy was treated successfully with antibiotics and PMX-DHP.2. Clinical report
A 49-year-old Japanese male smoker with SCLC was admitted
for chemotherapy. His performance status (PS) was good (PS ¼ 0).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Fig. 1). At that time, he had been treated with cisplatin (CDDP: 60
mg/m2) and irinotecan (CPT-11: 60 mg/m2) as ﬁrst-line chemo-
therapy. Since the chest CT scan on his admission to our institution
revealed the reduction of tumor size (reduction rate: 75%, Fig. 1) by
chemotherapy, he was admitted for the administration of a third
cycle of chemotherapy. On day 6 of the third cycle, he had become
febrile with severe diarrhea. Despite the intravenous administra-
tion of sulbactam/ampicillin sodium (SBT/ABPC), life-threatening
severe sepsis developed and he was transferred to the intensive
care unit (ICU) the same day.
The physical examination on transfer to the ICU revealed the
body temperature of 38.9 C, blood pressure 67/42 mmHg, regular
pulse 152 beats/min and oxygen saturation 86% under 3 L/min of
oxygen. The patient's skin was not ﬂushed, and lung auscultation
was the normal respiratory sound.
The results of the laboratory data and an arterial blood gas
analysis under 3 L/min of oxygen (Table 1) showed a white blood
cell count 19,100/mm3, hemoglobin 10.2 g/dL, platelet count
18,000/mm3, C-reactive protein (CRP) 24.4mg/dl, endotoxin 8.4 pg/
mL, pH 7.23, PaCO2 23.2 Torr, PaO2 45.9 Torr, and lactic acid 7.7
mmol/L. The SOFA score was 11 (PaO2/FiO2 ratio 139, platelet count
18,000/mm3, serum bilirubin 1.4 mg/dL, dopamine <5 mg/kg/min,
Glasgow Coma Scale 13, and serum creatinine 1.33 mg/dL), and theFig. 1. Chest CT at the diagnosis of SCLC and 3 months later at admission. (A) Chest CT at
Japanese male smoker. The chest CT shows the primary tumor shadow in the left superior
ductions of size in both the primary tumor shadow and the lymph node metastasis are obdisseminated intravascular coagulation (DIC) score was 5 (systemic
inﬂammatory response syndrome [SIRS] score 4, platelet count
18,000/mm3, prothrombin time  1.2, and ﬁbrinogen degradation
products 8.38 mg/dL).
The laboratory data revealed that the patient's SCLC was
complicated by syndrome of inappropriate secretion of antidiuretic
hormone (SIADH; plasma osmolality 264 mOsm/kg, urine osmo-
lality 524 mOsm/kg, urine sodium concentration 65 mEq/L, serum
sodium 127 mEq/L, serum creatinine 0.61 mg/dL, plasma cortisol
39.7 mg/dl, and antidiuretic hormone 1.1 pg/mL). A chest X-ray
showed no abnormal shadows, such as consolidations, except for
shadows of the main tumor and lymph node metastasis (Fig. 2).
Although a sputum culture was negative, blood cultures from the
intermediate cubital vein and right radial artery revealed
P. agglomerans.
After the patient's transfer to the ICU, his antibiotic therapy was
changes to tazobactam/piperacillin (TAZ/PIPC) and gentamicin
(GM) for a total of 14 days, and he underwent PMX-DHP for 2
consecutive days (Fig. 3). Additionally, red cell concentrates-
mannitol adenine phosphate (RCC-MAP), platelet concentrates-
leukocytes reduced (PC-LR) and fresh frozen plasma-leukocytes
reduced (FFP-LR) were transfused and recombinant thrombomo-
dulin was administered for the patient's DIC.
On day 9, the patient recovered from the septic shock, and thethe diagnosis of SCLC (3 months prior to this admission) in the patient, a 49-year-old
lobe and lymph node metastasis in the mediastinum. (B) Chest CT on admission. Re-
served.
Table 1
The laboratory data on admission.
<Hematology> <Biochemistry> <Coagulation>
WBC 19100/m3 TP 5.73 g/dl PT-INR 1.74
Neut. 93.9% BUN 20.0 mg/dl APTT 36.1 sec
Lymph. 2.8% Cre 1.33 mg/dl D-dimer 5.12 mg/mL
Mono. 2.9% AST 17 IU/L FDP 9.2 mg/mL
RBC 317  104/mm3 ALT 20 IU/L Fibrinogen 476 mg/mL
Hb 10.2 g/dl LDH 248 IU/L <Others>
Plt 1.8  104/mm3 Na 127 mEq/L ADH 1.1 pg/dl
K 3.0 mEq/L Cortisol 39.7 mg/dl
Cl 90 mEq/L urine Na 127 mEq/L
CRP 24.4 mg/dl plasma osmolality 264 mOsm/Kg
Endotoxin 8.4 pg/dl urine osmolality 524 mOsm/Kg
Fig. 2. Chest X-ray on transfer to the intensive care unit. Chest X-ray on transfer to the
ICU. The chest X-ray shows enlargement of left hilar shadow (arrow) without
consolidations.
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good response to these therapies, including the antibiotics and
PMX-DHP, and hewas released from the ICU on day 11. On day 12 ofFig. 3. Clinical course in the intensive care unit. Changes in the SOFA score, DIC score, CRP lev
SOFA score, DIC score, and CRP level dropped from 11 to 3, from 7 to 1, and from 24.4 mg/the third cycle of chemotherapy, the TAZ/PIPC and GM were dis-
continued and his treatment was switched to daily intravenous
ﬂomoxef for 7 days. By the end of the antibiotics therapy, the blood
cultures were negative. Although the patient underwent second-
and third-line chemotherapy, carboplatin þ etoposide and amru-
bicin, respectively, he died due to lymphangitis carcinomatosa at 15
months after the SCLC diagnosis.
3. Discussion
This is the ﬁrst report of the clinical presentation and course of
treatment by PMX-DHP for septic shock due to a P. agglomerans
infection in a patient with SCLC with SIADH.
P. agglomerans is a gram-negative rod bacterium commonly
found in soil, plants and the feces of humans and animals. Noso-
comial infection caused by P. agglomerans is rare [3]. Few reports
are available on sepsis due to P. agglomerans in patients with cancer,
while reports of 16 cases are available in the English literature
[3,4,8,11]. The mortality rate of patients with sepsis due to
P. agglomerans among adults and neonates were 11.1% [4] and 55.5%
[12], respectively. With regard to the effective antimicrobial treat-
ment of P. agglomerans infection, the antimicrobial susceptibility in
patients with bacteremia was measured as follows: fosfomycin
(FOM), 33%; ampicillin (ABPC), 56%; cefazolin (CEZ), 61%; cefotax-
ime (CTX), 100%; ceftazidime (CAZ), 100%; piperacillin-tazobactam
(PIPC/TAZ), 100%; imipenem (IPM), 100%; ciproﬂoxacin (CPFX),
100%; gentamicin (GM), 100% and amikacin (AMK), 100% [4].el and lactate level. After PMX-DHP treatment and the administration of antibiotics, the
dl to 3.3 mg/dl, respectively during the patient's 5-day stay in the ICU.
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minimal inhibitory concentration [MIC]) of cultured
P. agglomerans showed characteristics similar to those of a pre-
vious report as follows: ABPC, intermediate (MIC, 16.0 mg/mL);
CEZ, susceptible (MIC <4.0 mg/mL); CTX, susceptible (MIC <8.0
mg/mL); CAZ, susceptible (MIC <1.0 mg/mL); PIPC/TAZ, susceptible
(MIC <16.0 mg/mL); meropenem (MEPM), susceptible (MIC <1.0
mg/mL); CPFX, susceptible (MIC <0.5 mg/mL); GM, susceptible
(MIC <1.0 mg/mL) and AMK, susceptible (MIC <4.0 mg/mL). In a
cohort of adults, the patients with bacteremia who received
effective empirical antibiotics had a high cure rate (88.9%) [4].
Thus, the antibiotics recommended as empiric antimicrobial
therapy were PIPC/TAZ and carbapenem, according to the anti-
microbial susceptibility.
Several routes of P. agglomerans infection such as catheter [13]
and thorn injury [5] have been proposed. In our patient's case,
although central venous and pulmonary artery catheters were not
used and no bacterial body grew from sputum culture and the chest
X-ray showed no consolidations on transfer to the ICU, grade 3
diarrhea appeared (Common Terminology Criteria for Adverse
Events, ver. 4.0) after irinotecan-based chemotherapy. Intestinal
mucositis is a common side effect of irinotecan [14], and it can
cause bacteremia [15]. The intestinal epithelial damage caused by
irinotecan treatment leads to diarrhea and bacterial/endotoxin
translocation due to the disruption of the epithelial barrier, as se-
vere adverse effects [14,16].
It is unclear how our patient acquired a septic infection of
P. agglomerans, but it is possible that irinotecan-induced intestinal
mucositis cause the infection. The fact that P. agglomerans is one of
the gut bacteria, the non-use of central venous and pulmonary
artery catheters, our ﬁnding that the sputum culture grew no
bacterial body, and the presence of severe diarrhea all support this
possibility.
In our patient, we noted some parameters associated with poor
prognosis in sepsis; i.e., serum lactic acid [17], serum procalcitonin
[18] and hyponatremia [19]. In addition, hyponatremia induced by
SIADH (a paraneoplastic syndrome) is a strong prognostic factor in
SCLC patients [20]. In our patient, the levels of plasma osmolality,
urine osmolality, urine sodium, serum sodium, serum creatinine
and antidiuretic hormone, the non-use of diuretic agents, and the
normal thyroid and adrenal function satisﬁed the diagnostic
criteria of SIADH [21]. These data suggest that the mortality rate of
this type of case is very high.
With regard to the treatment of sepsis, this patient was treated
by PMX-DHP with the administration of antibiotics. Sepsis is
deﬁned as a systemic response to infection with the presence of
organ dysfunction [22]. It has been proposed that themechanism of
the progression of sepsis is an overwhelming reaction by innate
immunity products, infectious products and host products, such as
Toll-like receptor (TLR), LPS and high mobility group box 1
(HMGB1), respectively [22]. PMX-DHP removes integral compo-
nents of sepsis, including HMGB1 and LPS [23] and modulates the
circulating cytokine levels, such as those of interleukin (IL)-1 and
IL-6 [24]. Although the effectiveness of PMX-DHP in sepsis is
controversial, our patient's SOFA score was greatly reduced and his
DIC improved immediately after PMX-DHP treatment with antibi-
otics. PMX-DHP may thus have contributed to the improvement of
sepsis in this case.
In conclusion, we have described the case of an SCLC patient
with severe sepsis caused by P. agglomerans infection who was
treated successfully with antibiotics and PMX-DHP. Although the
efﬁcacy of PMX-DHP in sepsis is not well established, the combined
use of PMX-DHP and antibiotics should be considered in cases of
sepsis from gram-negative infections.Conﬂicts of interest
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